Broadcom named strategic vendor for Walmart virtualization solutions
SAN DIEGO - Poolbeg Pharma (AIM: POLB) revealed significant findings from its pre-clinical study of POLB 001 at the 66th American Society of Hematology Annual Meeting held in San Diego, California. The data presented indicates that all doses of POLB 001 substantially reduced Cytokine Release Syndrome (CRS) scores, a common complication associated with cancer immunotherapies.
During the study, POLB 001 demonstrated a dose-dependent reduction in clinical CRS scores and statistically significant reductions in peak serum levels of various key cytokines, including TNF, IL-4, IL-6, IL-8, and MIP-1α. This positions POLB 001 as a potential preventative therapy for CRS, which can occur in a significant percentage of patients treated with T cell engaging bispecific antibodies or CAR T cell therapies.
POLB 001, an oral p38 MAPK inhibitor, was compared to Adalimumab, a current potent inhibitor of CRS. The study involved humanized tumor-bearing mouse models treated with either placebo or varying doses of POLB 001. The results showed that POLB 001 was more effective in cytokine inhibition compared to Adalimumab.
Consultant Clinical Advisor for Poolbeg, Dr. Mark Sumeray, emphasized the impact of these results on the treatment of hematological malignancies. Sumeray stated that the data supports the development of POLB 001 in a Phase 2 clinical study as a prophylactic for the prevention of immunotherapy-induced CRS. The previous successful trial in healthy human volunteers also corroborates these findings.
The potential market for POLB 001 is substantial, with independent research commissioned by Poolbeg estimating a market potential of approximately US$10 billion in Multiple Myeloma and Diffuse Large B-Cell Lymphoma alone. The broader development of cancer immunotherapies across various hematological malignancies and solid tumors could expand this opportunity even further.
Poolbeg Pharma, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel treatments for diseases with high unmet medical needs. The presentation of POLB 001's pre-clinical data is a significant milestone for the company, reinforcing its commitment to advancing innovative therapies in the oncology space. The information in this article is based on a press release statement from Poolbeg Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.